Skip to main content
. Author manuscript; available in PMC: 2017 Feb 9.
Published in final edited form as: Breast Cancer Res Treat. 2016 Feb 9;155(3):431–440. doi: 10.1007/s10549-016-3698-y

Fig. 4.

Fig. 4

Effect of targeting β1 integrin in combination with HER2 or HER3. Nude mice bearing HCC1569TR-shHER3 tumor xenografts were randomly assigned to control (n = 7) or one of five treatment arms consisting of oral doxycycline (200 ug/ml) in drinking water (n = 8), AIIB2 administered twice weekly IP (1 mg/kg) (n = 8), daily lapatinib by oral gavage (50 mg/kg) (n = 8), or the indicated combinations (n = 8, n = 8). Treatments were terminated after 12 days and the mice were continuously monitored thereafter in the post-treatment phase. Error bars indicated the standard error of the mean. The increased efficacy of HER3 and β1 integrin targeting compared with HER2 and β1 integrin targeting is highly significant (AIIB2 + dox vs AIIB2 + lapatinib; comparison at day 24, two-tailed t test p < 0.0001)